by Maria Zannes | Mar 31, 2025 | Press Releases
Increased Demand, Expanded Insurance Coverage Drive Record Growth SAN ANTONIO, Texas (March 31, 2025) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage...
by Maria Zannes | Mar 26, 2025 | Press Releases
Case Demonstrates Benefit of Integrating CyPath® Lung into Standard of Care for Patients Under Surveillance After Treatment for Previous Lung Cancer SAN ANTONIO, Texas (March 26, 2025) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) today released a case study...
by Maria Zannes | Mar 19, 2025 | Press Releases
Case Demonstrates CyPath® Lung’s Potential in Guiding Oncological Care SAN ANTONIO, Texas (March 19, 2025) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) today released a study of a complex clinical case in which CyPath® Lung’s real-time assessment of the lung...
by Maria Zannes | Mar 14, 2025 | Articles, News
As published by 360Dx, March 14, 2025 By Greg Cima NEW YORK – BioAffinity Technologies said that it is cutting costs in its pathology lab and preparing to start a clinical trial for its sputum-based lung cancer test in a bid to expand into a national player in cancer...
by Maria Zannes | Mar 13, 2025 | Press Releases
SAN ANTONIO, Texas (March 13, 2025) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) announced the release of physicians’ case studies showing the benefit to patients and their doctors of using CyPath® Lung, the Company’s noninvasive test for early detection of...
